Opioid prescribing by oral and maxillofacial surgeons in the United States, 2016–2019

IF 1.8 4区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE Journal of public health dentistry Pub Date : 2022-10-09 DOI:10.1111/jphd.12544

Tumader Khouja BDS, MPH, PhD, Deborah E. Polk PhD, Katie J. Suda PharmD, MS, FCCP

{"title":"Opioid prescribing by oral and maxillofacial surgeons in the United States, 2016–2019","authors":"Tumader Khouja BDS, MPH, PhD, Deborah E. Polk PhD, Katie J. Suda PharmD, MS, FCCP","doi":"10.1111/jphd.12544","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To describe opioid prescribing trends among oral and maxillofacial surgeons (OMFS).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Prescriptions by OMFS were identified from IQVIA Longitudinal Prescription Dataset, 2016–2019. OMFS-based, patient-based and population-based prescribing rates and changes in high-risk opioid prescribing were calculated annually. We used linear regression to describe trends.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 13.9 million opioid prescriptions among 12.5 million patients (627 prescriptions/OMFS/year). Hydrocodone and oxycodone decreased by 20.9% and 39.2% (<i>p</i> < 0.05), while tramadol and codeine increased by 24.3% and 6.1% (<i>p</i> < 0.05), respectively. Opioid prescribing rates significantly decreased by 27 prescriptions/OMFS/year, 18.6 patients/OMFS/year and by 0.9 prescriptions/100,000 population/year (<i>p</i> < 0.05 for all). From 2016 to 2019, the proportion of opioids >3 days decreased by 54.2% (<i>p</i> < 0.05) and prescriptions ≥50 MME/day decreased by 66.3% (<i>p</i> < 0.05). Although the number of opioid prescriptions by OMFS decreased in most states, 12% of states experienced increases.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Opioid prescribing, especially high-risk prescribing, by OMFS has decreased. However, targeted interventions are warranted in some areas.</p>\n </section>\n </div>","PeriodicalId":16913,"journal":{"name":"Journal of public health dentistry","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of public health dentistry","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jphd.12544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 3

Abstract

Objective

To describe opioid prescribing trends among oral and maxillofacial surgeons (OMFS).

Methods

Prescriptions by OMFS were identified from IQVIA Longitudinal Prescription Dataset, 2016–2019. OMFS-based, patient-based and population-based prescribing rates and changes in high-risk opioid prescribing were calculated annually. We used linear regression to describe trends.

Results

There were 13.9 million opioid prescriptions among 12.5 million patients (627 prescriptions/OMFS/year). Hydrocodone and oxycodone decreased by 20.9% and 39.2% (p < 0.05), while tramadol and codeine increased by 24.3% and 6.1% (p < 0.05), respectively. Opioid prescribing rates significantly decreased by 27 prescriptions/OMFS/year, 18.6 patients/OMFS/year and by 0.9 prescriptions/100,000 population/year (p < 0.05 for all). From 2016 to 2019, the proportion of opioids >3 days decreased by 54.2% (p < 0.05) and prescriptions ≥50 MME/day decreased by 66.3% (p < 0.05). Although the number of opioid prescriptions by OMFS decreased in most states, 12% of states experienced increases.

Conclusion

Opioid prescribing, especially high-risk prescribing, by OMFS has decreased. However, targeted interventions are warranted in some areas.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2016-2019年美国口腔颌面外科医生开具的阿片类药物处方

目的了解口腔颌面外科医生(OMFS)的阿片类药物处方趋势。方法选取2016-2019年IQVIA纵向处方数据集中经OMFS鉴定的处方。每年计算基于omfs、基于患者和基于人群的处方率和高危阿片类药物处方的变化。我们用线性回归来描述趋势。结果1250万例患者中有1390万张阿片类药物处方(627张/OMFS/年)。氢可酮和羟考酮分别下降20.9%和39.2% (p < 0.05)，曲马多和可待因分别上升24.3%和6.1% (p < 0.05)。阿片类药物处方率显著下降，分别为27张/OMFS/年、18.6名患者/OMFS/年和0.9张/10万人/年(均p < 0.05)。2016 - 2019年阿片类药物使用3天的比例下降54.2% (p < 0.05)，处方≥50 MME/天的比例下降66.3% (p < 0.05)。虽然OMFS开出的阿片类药物处方数量在大多数州有所减少，但12%的州出现了增加。结论OMFS开具阿片类药物处方，特别是高危处方有所减少。然而，在某些领域有针对性的干预是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of public health dentistry 医学-公共卫生、环境卫生与职业卫生

CiteScore

3.80

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Public Health Dentistry is devoted to the advancement of public health dentistry through the exploration of related research, practice, and policy developments. Three main types of articles are published: original research articles that provide a significant contribution to knowledge in the breadth of dental public health, including oral epidemiology, dental health services, the behavioral sciences, and the public health practice areas of assessment, policy development, and assurance; methods articles that report the development and testing of new approaches to research design, data collection and analysis, or the delivery of public health services; and review articles that synthesize previous research in the discipline and provide guidance to others conducting research as well as to policy makers, managers, and other dental public health practitioners.